Dai Huibo, Ma Bangyun, Dai Xingbin, Pang Jie, Wang Jingyu, Zhao Yandong, Wang Mengya, Zhang Hong, Gao Haoran, Qian Shushu, Tian Fang, Sun Xuemei
Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Department of Hematology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China.
Front Pharmacol. 2021 Mar 29;12:585286. doi: 10.3389/fphar.2021.585286. eCollection 2021.
Shengma Biejia decoction (SMBJD), a traditional Chinese formula recorded in the , has been widely used for the treatment of malignant tumors. However, its underlying molecular targets and mechanisms are still unclear. This study showed that SMBJD inhibited tumor growth and stimulated hemogram recovery significantly in a multiple myeloma xenograft model. Western blot and immunohistochemistry assays of tumor tissues showed that SMBJD reduced the ratio of autophagy-related proteins LC3-II/LC3-I, while P62 and apoptosis-related proteins cleaved caspase-3/caspase-3 and Bax/Bcl-2 were upregulated. experiments demonstrated the time-dependent and dose-dependent cytotoxicity of SMBJD on multiple myeloma cell lines H929 and U266 through MTT assays. The LC3-II/LC3-I ratio and number of GFP-LC3 puncta showed that SMBJD inhibited the autophagy process of H929 and U266 cells. Moreover, both SMBJD and 3-methyladenine (3-MA) caused a decrease in LC3-II/LC3-I, and SMBJD could not reverse the upregulation of LC3-II/LC3-I caused by bafilomycin A1 (Baf-A1). Furthermore, the results of annexin V-FITC and propidium iodide double staining demonstrated that SMBJD treatment induced the apoptosis of H929 and U266 cells. These data prove that SMBJD inhibits autophagy and promotes apoptosis in H929 and U266 cells. The results also show that rapamycin could reduce the rate of SMBJD-induced apoptosis in H929 and U266 cells, at a concentration which had no effect on apoptosis but activated autophagy. In addition, analysis of the mechanism indicated that levels of phosphorylated ERK and phosphorylated mTOR were increased by treatment with SMBJD and . These results indicate that SMBJD, an old and effective herbal compound, could inhibit the viability of H929 and U266 cells and induce autophagy-mediated apoptosis through the ERK/mTOR pathway. Thus, it represents a potential therapy strategy for multiple myeloma.
升麻鳖甲汤(SMBJD)是《 》中记载的一种传统中药方剂,已被广泛用于治疗恶性肿瘤。然而,其潜在的分子靶点和机制仍不清楚。本研究表明,在多发性骨髓瘤异种移植模型中,升麻鳖甲汤显著抑制肿瘤生长并促进血常规恢复。对肿瘤组织进行的蛋白质免疫印迹和免疫组织化学分析表明,升麻鳖甲汤降低了自噬相关蛋白LC3-II/LC3-I的比例,而P62以及凋亡相关蛋白裂解的caspase-3/caspase-3和Bax/Bcl-2上调。通过MTT试验,实验证明了升麻鳖甲汤对多发性骨髓瘤细胞系H929和U266具有时间依赖性和剂量依赖性细胞毒性。LC3-II/LC3-I比例和GFP-LC3斑点数量表明,升麻鳖甲汤抑制了H929和U266细胞的自噬过程。此外,升麻鳖甲汤和3-甲基腺嘌呤(3-MA)均导致LC3-II/LC3-I降低,且升麻鳖甲汤无法逆转巴佛洛霉素A1(Baf-A1)引起的LC3-II/LC3-I上调。此外,膜联蛋白V-FITC和碘化丙啶双重染色结果表明,升麻鳖甲汤处理诱导了H929和U266细胞凋亡。这些数据证明,升麻鳖甲汤在H929和U266细胞中抑制自噬并促进凋亡。结果还表明,雷帕霉素可降低升麻鳖甲汤诱导H929和U266细胞凋亡的速率,其浓度对凋亡无影响,但可激活自噬。此外,机制分析表明,用升麻鳖甲汤 和 处理可提高磷酸化ERK和磷酸化mTOR的水平。这些结果表明,升麻鳖甲汤作为一种古老且有效的草药化合物,可抑制H929和U266细胞的活力,并通过ERK/mTOR途径诱导自噬介导的凋亡。因此,它代表了一种潜在的多发性骨髓瘤治疗策略。